Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities

Jii Bum Lee,Yiqing Huang,Yuko Oya,Jorn Nutzinger,Yvonne LE Ang,Kenneth Sooi,Byoung Chul Cho,Ross A Soo
DOI: https://doi.org/10.1016/j.lungcan.2024.107862
IF: 6.081
Lung Cancer
Abstract:Despite the efficacy of immunotherapy in non-small cell lung cancer (NSCLC), the majority of the patients experience relapse with limited subsequent treatment options. Preclinical studies of various epithelial tumors, such as melanoma and NSCLC, have shown that harnessing the gut microbiome resulted in improvement of therapeutic responses to immunotherapy. Is this review, we summarize the role of microbiome, including lung and gut microbiome in the context of NSCLC, provide overview of the mechanisms of microbiome in efficacy and toxicity of chemotherapies and immunotherapies, and address current ongoing clinical trials for NSCLC including fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs).
What problem does this paper attempt to address?